NLS Pharmaceutics .(NLSP) - 2023 Q4 - Annual Report

FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR Switzerland (Jurisdiction of incorporation or organization) The Circle 6 8058 Zurich Switzerland (Address of principal executive of ices) Alexander Zwyer Chief Executive Officer Tel: +41 44 512 21 50 contact@nls-pharma.com The Circle 6, Postfach 8058 Zurich Switzerlan ...